

## Synthesis of Novel Quinazoline Derivatives via Pyrimidine *ortho*-Quinodimethane

R. Chioua<sup>1\*</sup>, F. Benabdelouahab<sup>1</sup>, M. Chioua<sup>2</sup>, R. Martínez-Alvarez<sup>2</sup> and A. Herrera Fernández<sup>2</sup>.

<sup>1</sup> Département de Chimie, Université Abdelmalek Essaâdi, Faculté des Sciences, B.P 2121, Tétouan, Morocco. Tel. (+212) 39 97 24 23, Fax (+212) 39 99 45 00.

<sup>2</sup> Departamento de Química Orgánica I, Facultad de Ciencias Químicas, Universidad Complutense, E-28040, Spain. Tel. (+34) 91-3944205, Fax (+34) 91-3944103, E-mail [aherrera@eucmax.sim.ucm.es](mailto:aherrera@eucmax.sim.ucm.es)

\* Author to whom correspondence should be addressed; E-mail [rchioua@hotmail.com](mailto:rchioua@hotmail.com)

Received: 24 September 2001; in revised form: 3 July 2002 / Accepted: 8 July 2002 / Published: 31 July 2002

---

**Abstract:** The [4+2] cycloaddition between 2,4-diphenylpyrimidine *ortho*-quinodimethane and dimethyl acetylenedicarboxylate leads to 2,4-diphenylquinazoline-6,7-dicarboxylate (**6**). 2,4-Diphenylfuro[3,4-g]quinazoline-6,8-dione (**7**) is also obtained by basic hydrolysis of compound **6**, followed by the closure of the resulting diacid in acetic anhydride.

**Keywords:** [4+2] Cycloaddition, Diels-Alder adduct, dimethyl 2,4-diphenylquinazoline dicarboxylate.

---

### Introduction


The presence of a pyrimidine nucleus in many heterocyclic compounds, for example, the quinazolines, often leads to very interesting biological and pharmaceutical activities [1,2] so many methods for preparing quinazolines are reported in the literature [3,4]. In this work, we have developed an original method to prepare novel quinazoline derivatives based on cycloaddition between 2,4-disubstituted pyrimidine *ortho*-quinodimethanes and suitable dienophiles [5].

## Results and Discussion

The 2,4-diphenylpyrimidine *ortho*-quinodimethanes **4** were obtained according to a reported method [5]. The reaction of cyclobutanone (**1**) with benzonitrile (**2**) and triflic anhydride (Tf<sub>2</sub>O) leads to the formation in one step of 3,5-diphenyl-2,4-diaza-bicyclo[4.2.0]octa-1(6),2,4-triene (**3**) in moderate yield.

Heating compound **3** in *o*-dichlorobenzene (ODCB) at 180°C leads to the *in situ* generation of the extremely reactive pyrimidine diene **4**, which was further reacted with dimethyl acetylenedicarboxylate (**5**), via a [4+2]cycloaddition, to give the Diels-Alder adduct dimethyl 2,4-diphenylquinazoline-6,7-dicarboxylate (**6**) in 50 % yield in which loss of H<sub>2</sub> has occurred.

Scheme 1



The diester **6** when treated with a 1N solution of NaOH, afforded the expected 2,4-diphenylquinazoline-6,7-dicarboxylic acid in quantitative yield after two hours of stirring at 80°C. Subsequent heating of the diacid in acetic anhydride leads to 2,4-diphenylfuro[3,4-g]quinazoline-6,8-dione (**7**) (Scheme 1).

## Conclusions

We have presented an easy method for the formation of dimethyl 2,4-diphenylquinazoline-6,7-dicarboxylate. Basic hydrolysis of this diester followed by the closure of the resulting diacid in acetic anhydride gives 2,4-diphenylfuro[3,4-g]quinazoline-6,8-dione. This result opens an access for the

synthesis of other interesting derivatives such as the  $\beta$ -amino acid derivatives of quinazoline which could exhibit interesting biological activity. The synthesis of these compounds is underway in our laboratory.

## Acknowledgements

We are grateful to the Agencia Española de Cooperación Internacional (AECI) for financial support. We thank the Centro de Espectroscopía de la UCM for determining NMR and mass spectra.

## Experimental

### General

$^1\text{H}$ - and  $^{13}\text{C}$ -NMR spectra were obtained using *Varian VXR 300S*, *Bruker AC-200* and *Bruker AM-300* instruments. Melting points were determined on a *Gallenkamp* apparatus and are uncorrected. IR spectra were recorded on a *Shimadzu FTIR 8300*. The 70 eV mass spectra were recorded using a HP5989A quadrupole instrument (Hewlett Packard, Palo Alto, CA, USA) with a source temperature of 250°C.

### Synthesis of dimethyl 2,4-diphenylquinazoline-6,7-dicarboxylate (6).

2,4-Diphenylcyclobutapyrimidine (**3**, 200 mg, 0.77 mmol) was refluxed with dimethyl acetylenedicarboxylate (**5**, 0.2 mL) in *o*-dichlorobenzene (5 mL) at 180°C for 48 h. The solvent was removed under vacuum and the residue was subjected to silica gel chromatography with hexane/ethyl acetate (8:2) as the eluent. Compound (**6**) was thus obtained as a white solid (150 mg, 50 %), mp (from hexane): 156–158 °C;  $^1\text{H}$ -NMR ( $\text{CDCl}_3$ )  $\delta$ : 3.86 (s, 3H,  $\text{CO}_2\text{CH}_3$ ), 3.94 (s, 3H,  $\text{CO}_2\text{CH}_3$ ), 7.48 (m, 3H,  $\text{C}_6\text{H}_5$ ), 7.58 (m, 3H,  $\text{C}_6\text{H}_5$ ), 7.83 (m, 2H,  $\text{C}_6\text{H}_5$ ), 8.36 (s, 1H, H-5), 8.52 (s, 1H, H-8), 8.64 (m, 2H,  $\text{C}_6\text{H}_5$ );  $^{13}\text{C}$ -NMR ( $\text{CDCl}_3$ )  $\delta$ : 53.05, 53.18, 128.78, 129, 129.13, 129.82, 130.37, 130.51, 130.72, 131.47, 137.79, 138.13, 155, 167.03, 167.16; IR (KBr)  $\text{cm}^{-1}$ : 1728, 1560, 1294, 1261, 1157; MS ( $m/z$ ): 398 ( $\text{M}^+$ ,  $\text{C}_{24}\text{H}_{18}\text{N}_2\text{O}_4$ , 78 %), 339 (100 %), 367 (31 %), 351 (42 %), 280 (64 %).

### Synthesis of 2,4-diphenylfuro[3,4-g]quinazoline-6,8-dione (7).

Dimethyl 2,4-diphenylquinazoline dicarboxylate (**6**) (150 mg, 0.37 mmol) and 1 N NaOH solution (2 mL) in methanol (5 mL) were heated for 2 h; after cooling the solution was concentrated under vacuum and the residue was dissolved in water (5 mL) and acidified with 2 N HCl solution. The resulting suspension was filtered to give 2,4-diphenylquinazoline-6,7-dicarboxylic acid (130 mg, 96 %), which was dissolved in acetic anhydride (5 mL) and heated under reflux for 2 h. After cooling, the product precipitated and was isolated by filtration (115 mg, 93 %), mp (from acetic anhydride): 280–282 °C;  $^1\text{H}$ -NMR ( $\text{DMSO-d}_6$ )  $\delta$ : 7.6 (m, 3H,  $\text{C}_6\text{H}_5$ ), 7.77 (m, 3H,  $\text{C}_6\text{H}_5$ ), 8 (m, 2H,  $\text{C}_6\text{H}_5$ ), 8.35 (s, 1H,

H-5), 8.53 (s, 1H, H-8), 8.69 (m, 2H, C<sub>6</sub>H<sub>5</sub>); IR (KBr) cm<sup>-1</sup>: 1716, 1687, 1616, 1600, 1388, 1244, 1215, 1170; MS (m/z): 352 (M<sup>+</sup>•, C<sub>22</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub>, 43 %), 351 (18 %), 283 (21 %), 280 (74 %), 280 (74 %), 149 (11 %), 105 (14 %).

## References

1. Szarics, E; Nyikos, L; Barabas, P; Kovacs, I; Skuban, N; Temesvarine-Major, E; Egyed, O; Nagy, P.I.; Kokosi, J; Takacs-Novak, K; Kardos, J. *Mol. Pharmacol.*, **2001**, *59*, 920-928.
2. Sielecki, T.M.; Johnson, T.L.; Liu, J; Muckelbauer, J.K.; Grafstrom, R.H.; Cox, S.; Boylan, J.; Burton, C.R.; Chen, H.Y.; Smallwood, A.; Chang, C.H.; Boisclair, M.; Benfield, P.A.; Trainor, G.L.; Seitz, S.P. *Bioorg. Med. Chem. Lett.*, **2001**, *11*, 1157-1160.
3. Hanusek, J; Hejtmankova, L; Kubicova, L; Sedlak, M. *Molecules*, **2001**; *6*, 323-337.
4. Shibuya, I; Gama, Y; Shimizu, M. *Heterocycles*, **2001**, *55*, 381-386.
5. Herrera, A; Martinez, R; Gonzalez, B; Illescas, B; Martin, N; Seoane, C. *Tetrahedron Lett.*, **1997**, *38*, 4873-4876.

*Sample Availability:* Available from the authors.

© 2002 by MDPI (<http://www.mdpi.org>). Reproduction is permitted for noncommercial purposes.